A Phase 2 interventional study of Maraviroc (UK-427,857) and Maraviroc (UK-427,857) in HIV, sponsored by ViiV Healthcare. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-11-10.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.
Among the 44 studies testing maraviroc in HIV Infections, this one is the 22nd largest by enrollment, is the only one that started in 2003, is one of 7 in phase 2, and was the 7th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →
Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 9 · Phase 4 15
First in 2002; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 36 across the 44 interventional studies. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 151st largest by enrollment of the 210 interventional ones that give a count, is one of 4 that started in 2003, is one of 48 in phase 2, and was the 121st registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing maraviroc in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Maraviroc (UK-427,857)
Drug: Maraviroc (UK-427,857)
Drug: Maraviroc (UK-427,857)
Drug: Maraviroc (UK-427,857)
Other: Placebo
150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
Also known as: Celsentri, Selzentry
100 mg oral tablet once daily while fasted on Days 1-10
Also known as: Celsentri, Selzentry
300 mg oral tablet once daily while fasted on Days 1-10
Also known as: Celsentri, Selzentry
150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
Also known as: Celsentri, Selzentry
Matching placebo oral tablet on Days 1-10 (fed and fasted)
Change from baseline in viral load
Time frame: Day 11
UK-427,857 pharmacokinetics
Time frame: Days 1-11
Physical examination
Time frame: Days 1, 11, 40
12-lead ECG
Time frame: Days 1-11 and Day 40
Relationship of change in viral load (baseline to Day 11) versus mean receptor saturation (Day 10)
Time frame: Days 1-11
Time course of viral load from baseline to follow-up
Time frame: Days 1-13 and Days 15, 19, 22, 25, 40
CCR5 receptor saturation
Time frame: Days 1, 5, 10, 11, 13, 15, 19, 40
Adverse events
Time frame: Days 1-40
Relationship of change in viral load (baseline to Day 11) versus baseline susceptibility (IC50 and IC90)
Time frame: Days 1-11
Laboratory safety
Time frame: Days 1, 3, 7, 11, 15, 40
Relationship of change in viral load (baseline to Day 11) versus average and trough plasma concentrations (Day 10)
Time frame: Days 1-11
Supine/standing blood pressure and pulse rate
Time frame: Days 1-11 and Day 40
Time to rebound of viral load
Time frame: Days 1-13 and Days 15, 19, 22, 25, 40
The record gives a start of Jul 2003 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc